Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility

• Published in: Biochemical pharmacology 2018-10, Vol.156, p.458-466
• Main Authors: Kuc, Norbert, Doermann, Allison, Shirey, Carolyn, Lee, Daniel D., Lowe, Chinn-Woan, Awasthi, Niranjan, Schwarz, Roderich E., Stahelin, Robert V., Schwarz, Margaret A.
• Format: Article
• Language: English
• Subjects: Ceramide-1-phosphate; Ceramides; Sphingolipids; Tumor dissemination
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2018.09.017

[Display omitted] •PDAC are a source of bioactive sphingolipid C1P.•PDAC secrete C1P-containing vesicles recruit PCSC.•Uptake of PDAC secreted C1P-vesicles in a peri-nuclear region of PCSC.•PDAC and PCSC co-injection reduces animal survival. The high mortality rate associated with pancreatic ductal adenocarcinoma (PDAC) is in part due to lack of effective therapy for this highly chemoresistant tumor. Cancer stem cells, a subset of cancer cells responsible for tumor initiation and metastasis, are not targeted by conventional cytotoxic agents, which renders the identification of factors that facilitate cancer stem cell activation useful in defining targetable mechanisms. We determined that bioactive sphingolipid induced migration of pancreatic cancer stem cells (PCSC) and signaling was specific to ceramide-1-phosphate (C1P). Furthermore, PDAC cells were identified as a rich source of C1P. Importantly, PDAC cells express the C1P converting enzyme ceramide kinase (CerK), secrete C1P-containing extracellular vesicles that mediate PCSC migration, and when co-injected with PCSC reduce animal survival in a PDAC peritoneal dissemination model. Our findings suggest that PDAC secrete C1P-containing extracellular vesicles as a means of recruiting PCSC to sustain tumor growth therefore making C1P release a mechanism that could facilitate tumor progression.